XASX
IIQ
Market cap15mUSD
Oct 07, Last price
0.16AUD
1D
-5.88%
1Q
-30.43%
Name
INOVIQ Ltd
Chart & performance
P/E
—
P/S
52.13
EPS
—
Div yield, %
—
Shrs. gr., 5y
11.30%
Rev. gr., 5y
-19.41%
Revenues
432k
-76.20%
Net income
-8m
L+8.26%
CFO
-6m
L+36.83%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Key people
Leearne Maree Hinch
Chief Executive Officer
Irmgard Irminger-Finger
Chief Scientific Officer, Executive Director · since 2016
Peter Lynton Gunzburg
Executive Chairman of the Board · since 2017
Director · since 2019
Allan William Cripps
Non-Executive Independent Director · since 2020
Legal address
'Tempo Building' Unit B1, 431 Roberts Road
SUBIACO, WA 6008
AU
SUBIACO, WA 6008
AU
Headquarters
PO Box 7493, Cloisters Square
Perth, WA 6850
AU
Perth, WA 6850
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||